Jejunal Intussusception from Polypoid Formation of Primary Intestinal Lymphoma in Crohn’s Disease: Case Report and Literature Review
Giungato S*, De Luca GM, Borrello G, Mazzoccoli G, Marangi G, Piscitelli D, Scoletta C and Pepe AS
Giungato S1*, De Luca GM2, Borrello G3, Mazzoccoli G3, Marangi G4, Piscitelli D5, Scoletta C1 and Pepe AS1
1Unit of Surgery and Endoscopy, Department of Emergency Surgery, San Pio Hospital, Italy
2Unit of Surgery, Department of Emergency Surgery, Camberlingo Hospital, Italy
3Unit of Radiology, Department of Emergency, San Pio Hospital, Italy
4Unit of Pathology, Department of Emergency Surgery, SS. Annunziata Hospital, Italy
5Unit of Pathology, Department of Emergency Surgery and Organ Transplantation, University Medical School, Italy
Background: Crohn’s disease is a type of clinical form of inflammatory bowel disease represented by chronic gastrointestinal disorder caused by an inappropriate immune-mediated response and primary gastrointestinal lymphoma accounts for 4% to 20% of all non-Hodgkin’s lymphoma cases, above all B-cell lymphoma, in CD patients.
Case report: A 49-year-old woman, affected by Crohn’s disease, was admitted for the second time, after 21 months, at our Surgical Emergency Unit for acute abdomen for bowel occlusion. The patient had not been submitted to biological therapy. She was submitted to CT-Scan and PET-CT that showed pseudo-aneurismatic dilatation of bowel. Jejunal-jejunal intussusception in the site of previous anastomosis was observed with histological diagnosis of T-cell Non-Hodgkin Intestinal Lymphoma. Discharged after 16 days and she died after 3 months.
Methods: We have compared our case with the literature for the presence of intestinal lymphoma in CD that has not been submitted to biological therapy, matching terms: Crohn’s disease and intestinale lymphoma case report; Crohn’s disease and intestinal lymphoma; Crohn’s disease and bowel lymphoma; Crohn’s disease and primary intestinal lymphoma.
Results: Analysis of 58 cases (including the present study) showed these characteristics: 41 male (70%) and 17 female (30%); middle age: 46,9 yr (range 12 – 84); Patients submitted to surgery: 13/32 (40%), not all studies reported this date; History of CD: 7,7 yr (range 1 – 48); palpable mass at admission: 6/28 (21%).
Conclusions: The association between CD and intestinal lymphoma is rare, but during the follow-up of the patient, the development of this serious complication must never be excluded. This kind of pathological association is not related to biological therapy but to the disease itself and, surely, to the long duration of the Thiopurine therapy.
Keywords: lymphoma; Intussusception; Crohn’s disease; Surgery
Crohn’s Disease (CD) is a type of clinical form of Inflammatory Bowel Disease (IBD) represented by chronic gastrointestinal disorder caused by an inappropriate immune-mediated response.
The overall prevalence of inflammatory bowel disease (IBD) is approximately 0.4% in Europeans and North Americans . Over the last years, the treatment of IBD patients has changed with the birth of new drugs as immunomodulator and biological therapy.
The advent of biological therapy has represented an important achievement in the management of the CD but a close correlation between the same therapy and the development of lymphoproliferative disorders seems to be reported in the literature.
The incidence of lymphoma in the general population ranges from 15 to 100 cases/100,000 person-years, increasing the risk with age and family history .
Primary gastrointestinal lymphoma accounts for 4% to 20% of all non-Hodgkin’s lymphoma cases, above all B-cell lymphoma .
There have been several small population-based studies which could not detect an increased risk of lymphoma in the IBD population but we present a case report of a young woman affected by CD presenting an occlusive syndrome by jejunal intussusception caused by polypoid formation in intestinal lymphoma. We have compared our case with the literature for the presence of intestinal lymphoma in CD that has not been submitted to biological therapy.
Clinical Case Description
In February 2015 a 49-year-old woman was admitted at our Surgical Emergency Unit for acute abdomen. CT-scan showed bowel obstruction, for this reason the patient was submitted to surgical operation in emergency. Occlusion was caused by 10 cm stenotic tract of bowel at one meter from Treitz’ ligament. A bowel resection of 75 cm was performed with jejunal-jejunal anastomosis. Patient was discharged after 10 days with oral feeding. The patient didn’t have post-operative complications.
Histology showed extensive full thickness mucosal ulceration, with massive widespread chronic inflammatory lymphoplasmacellular infiltrate with histiocytic, granulocyte neutophilic and eosinophilic co-participation, and fibroblastic reaction of all the stenotic tract of the bowel. Crohn’s disease was diagnosed.
The patient was treated with 5-ASA (Mesalazine) at 4.8 g/day for 16 weeks and after with maintenance dosage, thiopurine at dosage of 1.5 mg/kg/day for 6 months.
After 21 months of well-being, the patient was re-admitted to our Hospital in emergency for abdominal pain, fever and palpable mass at left side of abdomen with two episodes of diarrhea in the same week (CDAI: 281,89). She was submitted to CT-Scan and magnetic resonance of the abdomen that revealed suspected anastomotic recurrence with a pseudoaneurismatic jejunal dilatation and for this reason was administered high dosage (4.8 g/day) of 5-ASA and 30 mg/Kg/day of corticosteroids endovenous therapy. Patient presented remission of abdominal pain, normal bowel canalization, no fever and the presence of the abdominal mass was reduced. She was discharged after 15 days (CDAI: 243,29) and she continued home therapy with 5-ASA and Prednisone 2.4 mg/Kg/day.
After 3 months the patient was re-admitted to our Operating Unit for abdominal pain, fever and palpable mass. No canalization of bowel and she was submitted to a PET-CT scan that confirmed pseudo-aneurismatic dilatation of bowel (Figures 1 and 2). She was submitted to surgical operation after enteral feeding equal to 900 kcal/day and total parenteral nutrition equal to 1700 kcal/day for one week.
Jejunal-jejunal intussusception in the site of previous anastomosis was observed. Transverse mesocolon ligament near the left colic flexure was occupied by a great neoplastic lesion of 20 cm diameter localized in the left hemiabdomen involving epiploon, Treitz’s ligament and descending colon (Figures 3-5). Multiple tough lymphnodes and ascitic fluid were highlighted. Jejunal intussusception was resected, approximately 30 cm of jejunum, and L-L jejunal-jejunal anastomosis was performed to solve bowel obstruction and cytological examination of ascitic fluid was drawn.
Histological findings showed “jejunal intussusception with polypoid formation of 6.5 cm diameter, hard consistency, compatible with T-cell Non-Hodgkin Intestinal Lymphoma” (Figures 6-8).
The patient had no post-operative complications and was discharged after 16 days. She was submitted to chemotherapy but she died after 3 months.
Materials and Methods
Literature analysis for systematic review was performed using main databases (Pubmed; Medline) matching terms: Crohn’s disease and intestinale lymphoma case report; Crohn’s disease and intestinal lymphoma; Crohn’s disease and bowel lymphoma; Crohn’s disease and primary intestinal lymphoma. Inclusion criteria of studies were: Paper written in English language; clinical cases of patients not submitted to biological therapy; case reports of patients affected by Crohn’s disease and intestinal lymphoma. Exclusion criteria were: Studies not written in English language; studies reporting only phisiopathological mechanisms; case reports of patients submitted to biological therapy; clinical cases reporting patients with other comorbidities.
881 studies have been analysed: Crohn’s disease and intestinal lymphoma case report (88 studies); Crohn’s disease and intestinal lymphoma (319 studies); Crohn’s disease and bowel lymphoma (408 studies); Crohn’s disease and primary intestinal lymhoma (66 studies). After removing duplicate studies, we have analysed 200 studies: 143 were removed because did not report clinical cases but fisiopathological mechanisms only; 4 studies were removed because reported patients submitted to biological therapy; 15 studies were excluded because reported patients affected by Crohn’s disease and intestinal lymphoma but with other associated immune-mediated pathology; 2 studies were excluded because reported association between Crohn’s disease and intestinal adenocarcinoma; 2 studied were excluded because were not written in English language. We resume literature analysis using Prisma flow diagram (Table 1).
34 studies have been included in our study and 57 cases presented Intestinal lymphoma in CD, not submitted to biological therapy, from 1955 up to now.
Analysis of 58 cases (including the present study) showed these characteristics: 41 male (70%) and 17 female (30%); middle age: 46,9 yr (range 12–84); Patients submitted to surgery: 13/32 (40%), not all studies reported this date; History of CD: 7,7 yr (range 1–48); palpable mass at admission: 6/28 (21%), not all studies reported this date (Table 2).
CD is an important clinical form of IBD, representing around 25% of patients with IBD, diagnosed in the first 2 decades of their life.
Currently, the highest annual incidence of CD in Europe is 12.7 per 100,000 person-years and primary intestinal lymphoma in CD patients is described as uncommon even if it is reported in many cases by now.
Treatment of CD, during these last decades has been revolutionized by the development of biological therapy. In fact, until the last century patients with CD were more often submitted to surgery, above all for bowel occlusion.
During the last decades some drugs have been developed to oppose autoimmunity, as thiopurines, and inflammation of mucosa, as 5-ASA.
At the end of the last decades were developed biological drugs (Infliximab, Adalimumab, Vedoluzimab, Natalizumab) that have improved the course of the disease. But in 1999, Bickston, et al. described 3 cases of CD patients, who underwent biological therapy with lymphoma disease .
Conversely in 2013 Burmester, et al. published a randomized study literature review with 4.000 patients affected by CD, proving an incidence rate of lymphomatous diseases in CD of 0.7% patient/ year .
In 2016 Van Den Heuvel et al. showed a Cohort study analyzing neoplastic correlations in patients affected by IBD, describing that the development of neoplasm in patients affected by IBD is not related to biological therapy but to duration of immunosuppressive therapy (Thiopurine) for more than 12 months .
There is reason to believe that thiopurines themselves have an effect as well. Thiopurines are suppressing the immune system and have specific procarcinogenic effects. In case of haematologic cancers, for instance, aziathioprine promotes clonal expansion of rare mismatch repair-defective myeloid cells. A potential mechanism in NMSC carcinogenesis is the accumulation of 6-thioguanine in DNA. Thiopurine exposure may also cause PTCH mutations, a candidate tumor suppressor gene, particularly in cancers from non-sun-exposed skin, such as BCC .
There have been several studies estimating the risk of lymphoma in the IBD population. A British study performed by Lewis, et al. included 6000 Crohn’s disease patients, 10000 ulcerative colitis patients, and 60000 matched controls, and did not show a significantly increased risk of lymphoma (risk ratio, 1.2) . A Swedish population-based study by Askling, et al. which included 47000 IBD patients, showed that the risk of any malignant lymphoma was 0.8 .
There have been several other small population-based studies which could not detect an increased risk of lymphoma in the IBD population. A 2011 Dutch nationwide study which included 17834 patients concluded that there was no increased risk for lymphoma in IBD (Risk Ratio 1.27) .
Our literature analysis reported a correlation between CD and Intestinal lymphoma with poor prognosis, therefore it is important to perform a quick diagnosis to immediately submit patients to chemotherapy. Radiological diagnosis is the most important method to make a fast diagnosis, as in 1976 Shapira, et al. already showed through the description of bowel aneurismatic dilatation in patients affected by intestinal lymphoma .
The association between CD and intestinal lymphoma is rare, but during the follow-up of the patient, the development of this serious complication must never be excluded, above all when the patient does not respond to the traditional therapy and when there is the presence of palpable abdominal mass. This kind of pathological association is not related to biological therapy but to the disease itself and, surely, to the long duration of the Thiopurine therapy.
1. Garg SK, Loftus EV Jr. Risk of cancer in inflammatory bowel disease: Going up, going down, or still the same?. Curr Opin Gastroenterol 2016;32:274-281.
2. Lewis JD. Risk of lymphoma in patients with inflammatory bowel disease. Gastroenterol Hepatol 2012;8:45-47.
3. Nakamura S, Matsumoto T, Lida M, et al. Primary gastrointestinal lymphoma in Japan: A clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 2003;97:2462-2473.
4. Hughes R. Reticulum cell sarcoma: A case possibly originating in regional enteritis. Ann Surg 1955;21: 770-773.
5. Darke SG, Parks AG, Grogono JL, et al. Adenocarcinoma and Crohn’s disease: A report of two cases and analysis of the literature. Br J Surg 1961;49:80-89.
6. Wyburn-Mason R. A new Protozoan: Its relation to malignant and other diseas. London: Kimpton, 1964
7. Fielding JF, Prior P, Waterhouse JA, et al. Malignancy in Crohn’s disease. Scand J Gastroenterol 1972;7:3-7.
8. Schofield PF. Intestinal malignancy and Crohn’s disease. Scand J Gastroenterol 1972;7:3-7.
9. Codling BW, Keighley MRB, Slaney G. Hodgkin’s disease complicating Crohn’s colitis. Surgery 1977;82:625-628.
10. Collin WJ. Malignant lymphoma complicating regional enteritis: case report and review of the literature. Am J Gastroenterol 1977;68:177-181.
11. Lee GB, Smith PM, Seal RM. Lymphosarcoma in Crohn’s disease: report of a case. Dis Colon Rectum 1977;20:351-354.
12. Hecker R, Sheers R, Thomas D. Hodgkin’s disease as a complication of Crohn’s disease. Med J Aust 1978;2:603.
13. Gyde SN, Prior P, Macartney JC, et al. Malignancy in Crohn’s disease. Gut 1980;21:1024-1029.
14. Morrison PD, Whittaker M. A case of Hodgkin’s disease complicating Crohn’s disease. Clin. Oncol 1982;8:271-272.
15. Shaw JH, Mulvaney N. Hodgkin’s lymphoma: a complication of small bowel Crohn’s disease. Aust NZ J Surg 1982;52:34-36.
16. Glick SN, Teplick SK, Goodman LE, et al. Development of lymphoma in patients with Crohn’s disease. Radiology 1984;153:337-339.
17. Kwee WS, Wils JAMJ, Van Den Tweel JG. Malignant lymphoma, immunoblastic with plasmacytic differentiation, complicating Crohn’s disease. Histopathology 1985;9:115-120.
18. Kini SU, Pai PK, Rao, et al. Primary gastric lymphoma associated with Crohn’s disease of the stomach. Am J Gatroenterol 1986;81:23-25.
19. Robertson EJ, Al-Kaisi NK, Vareska GJ, et al. Plasmocytoma of the ileum complicating Crohn’s disease: report of a case and review of the literature. Surgery 1986;100:916-922.
20. Williams JG, William GT, Gough J, et al. Primary malignant lymphoma of the large intestine. Coloproctology 1988;10:238-243.
21. Sheperd NA, Hall PA, William GT, et al. Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease. Histophatology 1989;15:325-337.
22. Perosio PM, Brooks JJ, Saul SH, et al. Primary intestinal lymphoma in Crohn’s disease: minute tumor with a fatal outcome. Am J Gastroenterol 1992;87:894-898.
23. Brown I, Schofield JB, Maclennan KA, et al. Primary non-Hodgkin’s lymphoma in ileal Crohn’s disease. Eur J Surg Oncol 1992;18:627-631.
24. Vanbockrijk M, Cabooter M, Casselman J, et al. Primary Hodgkin’s disease of the ileum complicating Crohn’s disease. Cancer 1993;72:1784-1789.
25. Maaravi Y, Wengrower D, Leibowitz G. A unique presentation of lymphoma of the colon. J Clin Gastroenterol 1993;17:49-51.
26. Woodley HE, Spencer JA, Maclennan KA. Small-bowel lymhpoma complicating long-standing Crohn’s disease [letter]. Am J Roentgenol 1997;169:1462-1463.
27. Kelly MD, Stuart M, Tschucchnigg M, et al. Primary intestinal Hodgkin’s disease complicating ileal Crohn’s disease. Aust N Z J Surg. 1997;67:485-489.
28. Calaminici MR, Sheaff MT, Norton AJ, et al. Ileocaecal Epstein-Barr virus-postive lymphoproliferative disorder complicating Crohn’s disease. Histopathology 1999;35:388-390.
29. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein Barr virus-positive primary gastorintestinal Hodgkin’s disease: association with inflammatory bowel disease and immunmosoppression. Am J Surg Pathol 2000;24:66-73.
30. Hall CH Jr, Shamma M. Primary intestinal lymphoma complicating Crohn’s disease. J Clin Gastroenterol 2003:36:332-336.
31. Raderer M, Puspok A, Birkner T, et al. Primary gastruc Mantle cell lymphoma in a patient with long stnading history of Crohn’s disease. Leuk Lymphoma 2004;45:1459-1462.
32. Aydogan A, Corapcioglu F, Elemen L, et al. Childhood non-hodgkin’s lumphoma arising as a complication early in the course of Crohn’s disease. Turk J Pediatr 2010;52:411-415.
33. Kashi MR, Belayev L, Parker A. Primary extranodal hodgkin lymphoma of the colon masquerading as new diagnosis of Crohn’s Disease. Clin Gastroenterol Hepatol 2010;8:A20.
34. Holubar SD, Dozois EJ, Loftus EV Jr, et al. Primary intestinal lymphoma in patients with inflammatory bowel disease: A descriptive series from the prebiologic therapy era. Inflamm Bowel Dis 2011; 17:1557-1563.
35. Iribarren-Marín MA, González-Martín R, Aguilar-García J, et al. Primary intestinal lymphoma associated with Crohn’s disease. Rev Esp Enferm Dig 2011;103:662-663.
36. Zheng S, Xu H, Ouyang Q, et al. A case of rapid growing colonic NK/T cell lymphoma complicated by Crohn’s disease. Chin J Cancer Res 2013;25:119-123.
37. Gibson B, Podill MB, Baumgartner EM, et al. Syncytial variant of nodular sclerosis classical hodgkin lymphoma of the terminal ileum in a patient with longstanding Crohn’s disease. Ann Clin Lab Sci 2016;46:219-221.
38. Bickston SJ, Lichester GR, Arseneau KO, et al. The relationship between infliximab treatmen and lymphoma in Crohn’s disease, Gastroenterol 1999;117:1433-1437.
39. Burmester GR, Panaccione R, Gordon KB, et al Adalimumab: Long-term safety in 23,458 patients from global clinical trials in rheumtaoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriac arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013;72:517-524.
40. van den Heuvel TR, Wintjens DS, Jeuring SF, et al. Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016;139:1270-1280.
41. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterol 2001;121:1080- 1087.
42. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-622.
43. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflamm Bowel Dis 2011;17:1837-1845.
44. Shapira Y, Zaidel L, Ravid M. Aneurysmatic dilatation of the duodenum and a nephrointestinl fistula in a case of abdominal lymphoma. Acta Hepatogastroenterol 1976;23:372-373.